You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恒瑞醫藥(600276.SH):注射用瑞康曲妥珠單抗藥品上市許可申請獲受理
格隆匯 09-13 16:06

格隆匯9月13日丨恒瑞醫藥(600276.SH)公佈,子公司蘇州盛迪亞生物醫藥有限公司收到國家藥品監督管理局下發的《受理通知書》,公司注射用瑞康曲妥珠單抗(SHR-A1811)的藥品上市許可申請獲國家藥監局受理,並且近日該產品已被納入優先審評程序。注射用SHR-A1811可通過與HER2表達的腫瘤細胞結合並內吞,在腫瘤細胞溶酶體內通過蛋白酶剪切釋放毒素,誘導細胞週期阻滯從而誘導腫瘤細胞凋亡。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account